Background:
Panitumumab is an EGFR inhibitor used for the treatment of metastatic
colorectal cancer (mCRC), even if its use is related to skin toxicity.
Case Presentation:
We report the development of forearm panniculitis in two women during the
treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5-
fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC.
Results:
In both patients, clinical, laboratory and radiological evaluation documented the presence
of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation
and antimicrobial + corticosteroid treatment induced a remission of skin manifestations.
Conclusion:
We reported for the first time the development of panniculitis during Panitumumab
treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or
oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with
mCRC, without the development of adverse drug reactions or drug-drug interactions.